update on age related maculopathy
TRANSCRIPT
![Page 1: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/1.jpg)
UPDATE ON AGE RELATED MACULAR DEGENERATION
DR KHALED AL KHALED, MD, MRCOPHTH
![Page 2: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/2.jpg)
INTRODUCTION
• AGE-RELATED MACULAR DEGENERATION (AMD) IS THE LEADING CAUSE OF ADULT BLINDNESS AND SEVERE VISUAL IMPAIRMENT IN INDUSTRIALIZED COUNTRIES
1BRESSLER NM. AGE-RELATED MACULAR DEGENERATION IS THE LEADING CAUSE OF BLINDNESS... JAMA 2004; 291:1900.
![Page 3: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/3.jpg)
DRY (ATROPHIC) AMD
![Page 4: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/4.jpg)
ANTIOXIDANT VITAMINS AND ZINC
• AREDS1:• VITAMIN C (500 MG)• VITAMIN E (400 IU)• BETA-CAROTENE (15 MG)• ZINC (ZINC OXIDE 80 MG)• CUPRIC OXIDE 2 MG
1AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP. A RANDOMIZED, PLACEBO-CONTROLLED, CLINICAL TRIAL OF HIGH-DOSE SUPPLEMENTATION WITH VITAMINS C AND E, BETA CAROTENE, AND ZINC FOR AGE-RELATED MACULAR DEGENERATION AND VISION LOSS: AREDS REPORT NO. 8. ARCH OPHTHALMOL 2001; 119:1417.
![Page 5: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/5.jpg)
ANTIOXIDANT VITAMINS AND ZINC• IN A META-ANALYSIS, 88 PERCENT OF PATIENTS WERE IN THE
AREDS COHORT, AND THE REVIEWERS CONCLUDED THAT THE OTHER STUDIES ADDED LITTLE TO THE EVALUATION
1AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP. A RANDOMIZED, PLACEBO-CONTROLLED, CLINICAL TRIAL OF HIGH-DOSE SUPPLEMENTATION WITH VITAMINS C AND E, BETA CAROTENE, AND ZINC FOR AGE-RELATED MACULAR DEGENERATION AND VISION LOSS: AREDS REPORT NO. 8. ARCH OPHTHALMOL 2001; 119:1417.2EVANS JR. ANTIOXIDANT VITAMIN AND MINERAL SUPPLEMENTS FOR SLOWING THE PROGRESSION OF AGE-RELATED MACULAR DEGENERATION. COCHRANE DATABASE SYST REV 2006; :CD000254.
![Page 6: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/6.jpg)
ANTIOXIDANT VITAMINS AND ZINC
2EVANS JR. ANTIOXIDANT VITAMIN AND MINERAL SUPPLEMENTS FOR SLOWING THE PROGRESSION OF AGE-RELATED MACULAR DEGENERATION. COCHRANE DATABASE SYST REV 2006; :CD000254.
![Page 7: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/7.jpg)
ANTIOXIDANT VITAMINS AND ZINC• AREDS2:
• ORIGINAL DOSE ZINC (80 MG AS ZINC OXIDE)• COPPER OXIDE (2 MG)• VITAMIN E (400 IU)• VITAMIN C (500 MG)• LUTEIN (10 MG) • ZEAXANTHIN (2 MG)• BETA-CAROTENE (15 MG)
1THE AGE-RELATED EYE DISEASE STUDY 2 (AREDS2) RESEARCH GROUP, LUTEIN + ZEAXANTHIN AND OMEGA-3 FATTY ACIDS FOR AGE-RELATED MACULAR DEGENERATION THE AGE-RELATED EYE DISEASE STUDY 2 (AREDS2) RANDOMIZED CLINICAL TRIAL. JAMA. 2013;309(19):2005-2015. DOI:10.1001/JAMA.2013.4997.
![Page 8: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/8.jpg)
![Page 9: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/9.jpg)
LASER THERAPY
1PARODI MB, VIRGILI G, EVANS JR. LASER TREATMENT OF DRUSEN TO PREVENT PROGRESSION TO ADVANCED AGE-RELATED MACULAR DEGENERATION. COCHRANE DATABASE SYST REV 2009; :CD006537. (UPDATED 2015)
![Page 10: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/10.jpg)
LASER THERAPY
![Page 11: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/11.jpg)
STEM CELLS THERAPY
• A PROSPECTIVE STUDY IN NINE PATIENTS WITH ATROPHIC AMD (MEDIAN AGE 77 YEARS) FOUND THAT:• SUBRETINAL TRANSPLANTATION OF HUMAN EMBRYONIC
STEM CELL-DERIVED RETINAL EPITHELIAL CELLS IMPROVED VISUAL ACUITY AT 12 MONTHS IN THE TREATED EYE COMPARED WITH THE UNTREATED EYE
![Page 12: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/12.jpg)
STEM CELLS THERAPY
![Page 13: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/13.jpg)
STEM CELLS THERAPY
• THESE FINDINGS SUPPORT A PROOF-OF-CONCEPT, BUT ARE TOO PRELIMINARY TO SUGGEST A MEANS OF TREATMENT.
![Page 14: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/14.jpg)
WET(NEOVASCULAR OR EXUDATIVE)
![Page 15: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/15.jpg)
RANIBIZUMAB (LUCENTIS)
• IS A RECOMBINANT HUMANIZED MONOCLONAL ANTIBODY WITH SPECIFICITY FOR VEGF. INTRAVITREAL RANIBIZUMAB IS AVAILABLE FOR THE TREATMENT OF WET AMD AT A DOSE OF 0.5 MG BY INTRAVITREAL INJECTION EVERY MONTH
• SEVERAL RANDOMIZED TRIALS OF PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION (AMD) HAVE SHOWN BENEFIT.
• THE MARINA TRIAL• THE ANCHOR TRIAL.. ETC..
1ROSENFELD PJ, BROWN DM, HEIER JS, ET AL. RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. N ENGL J MED 2006; 355:1419.2BROWN DM, KAISER PK, MICHELS M, ET AL. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. N ENGL J MED 2006; 355:1432.
![Page 16: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/16.jpg)
16
SAFETY PROFILE OF RANIBIZUMAB :
• SAFETY PROFILE OF RANIBIZUMAB SERIOUS OCULAR ADVERSE EVENTS IN 2 YEAR MARINA STUDY FOR RANIBIZUMAB 0.5 MG:
• ENDOPHTHALMITIS – 1.3% • UVEITIS – 1.3% .• RETINAL TEAR – 0.4%• LENS DAMAGE – 0.4%
![Page 17: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/17.jpg)
17
SAFETY PROFILE OF RANIBIZUMAB :
• SAFETY PROFILE OF RANIBIZUMAB SERIOUS OCULAR ADVERSE EVENTS IN 1 YEAR ANCHOR STUDY FOR RANIBIZUMAB 0.5 MG :
• ENDOPHTHALMITIS – 1.4 %• UVEITIS – 0.7% • THERE WAS NO INCREASE IN SYSTEMIC
ADVERSE EFFECTS SUCH AS HTN, ARTERIAL THROMBOEMBOLISM IN EITHER STUDY
![Page 18: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/18.jpg)
BEVACIZUMAB (AVASTIN)
• TREATMENT WITH INTRAVITREAL BEVACIZUMAB FOR AMD IS FAR LESS EXPENSIVE THAN TREATMENT WITH INTRAVITREAL RANIBIZUMAB.
• RANIBIZUMAB IS ESSENTIALLY AN ANTIBODY FRAGMENT (FAB FRAGMENT) OF BEVACIZUMAB WITH SOME MODIFICATIONS TO THE AMINO ACID SEQUENCE THAT INCREASE ITS BINDING OF VEGF.
• BEVACIZUMAB IS APPROVED IN THE UNITED STATES AS AN INTRAVENOUS INFUSION FOR THE SYSTEMIC THERAPY OF COLORECTAL CANCER.
![Page 19: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/19.jpg)
RANIBIZUMAB VS BEVACIZUMABSYSTEMATIC REVIEWS 1
![Page 20: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/20.jpg)
RANIBIZUMAB VS BEVACIZUMABSYSTEMATIC REVIEWS 1
![Page 21: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/21.jpg)
RANIBIZUMAB VS BEVACIZUMABSYSTEMATIC REVIEWS 2
![Page 22: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/22.jpg)
RANIBIZUMAB VS BEVACIZUMABSYSTEMATIC REVIEWS 2
![Page 23: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/23.jpg)
RANIBIZUMAB VS BEVACIZUMABSYSTEMATIC REVIEWS 2
FOREST PLOT SHOWING ESTIMATED RISK RATIOS (RRS) WITH THEIR 95% CONFIDENCE INTERVALS (CIS) FOR BEVACIZUMAB VERSUS RANIBIZUMAB FOR GAIN OF ≥15 LETTERS FROM BASELINE FOR EACH OF THE 6 INDIVIDUAL TRIALS AND COMBINED. A, ONE-YEAR FINDINGS. B, TWO-YEAR FINDINGS.
![Page 24: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/24.jpg)
AFLIBERCEPT (EYLEA)
• RECOMBINANT FUSION PROTEIN THAT COMPETES FOR BINDING OF VEGF AND THEREFORE HAS AN EFFECT SIMILAR TO VEGF INHIBITORS
• THE MOST RECENT DRUG TO BE APPROVED BY THE FDA FOR TREATING PATIENTS WITH WET AMD1 (2011).
• INSTEAD OF BEING AN ANTIBODY TO THE VEGF MOLECULE, IT IS A FUSION PROTEIN CONSISTING OF PORTIONS OF THE RECEPTORS FOR THE VEGF MOLECULE (VEGFR-1, VEGFR-2), THEREBY BINDING AND BLOCKING VEGF
1WWW.FDA.GOV/NEWSEVENTS/NEWSROOM/PRESSANNOUNCEMENTS/UCM280601.HTM
![Page 25: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/25.jpg)
26
AFLIBERCEPT (EYLEA)
• IN TWO RANDOMIZED TRIALS OF 2419 ADULT PATIENTS WITH WET AMD, INTRAVITREAL AFLIBERCEPT (0.5 MG MONTHLY, 2.0 MG MONTHLY, OR 2.0 MG EVERY TWO MONTHS) WAS SIMILARLY EFFECTIVE IN IMPROVING VISUAL ACUITY AT ONE AND TWO YEARS COMPARED WITH INTRAVITREAL RANIBIZUMAB 0.5 MG MONTHLY.
1HEIER JS, BROWN DM, CHONG V, ET AL. INTRAVITREAL AFLIBERCEPT (VEGF TRAP-EYE) IN WET AGE-RELATED MACULAR DEGENERATION. OPHTHALMOLOGY 2012; 119:2537.2SCHMIDT-ERFURTH U, KAISER PK, KOROBELNIK JF, ET AL. INTRAVITREAL AFLIBERCEPT INJECTION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: NINETY-SIX-WEEK RESULTS OF THE VIEW STUDIES. OPHTHALMOLOGY 2014; 121:193.
![Page 26: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/26.jpg)
AFLIBERCEPT (EYLEA)
![Page 27: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/27.jpg)
AFLIBERCEPT VS RANIBIZUMAB
• FOREST PLOT OF COMPARISON: 1 AFLIBERCEPT VS RANIBIZUMAB, OUTCOME: 1.1 MEAN CHANGE IN BCVA IN ETDRS LETTERS AT 1 YEAR.
• FOREST PLOT OF COMPARISON: 1 AFLIBERCEPT VS RANIBIZUMAB, OUTCOME: 1.2 GAIN OF ≥ 15 LETTERS OF BVCA AT 1 YEAR.
![Page 28: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/28.jpg)
AFLIBERCEPT VS RANIBIZUMAB
![Page 29: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/29.jpg)
AFLIBERCEPT VS RANIBIZUMAB
![Page 30: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/30.jpg)
AFLIBERCEPT VS RANIBIZUMAB
![Page 31: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/31.jpg)
AFLIBERCEPT VS RANIBIZUMAB
• AFLIBERCEPT IS LESS COSTLY THAN RANIBIZUMAB AND MAY ALLOW FOR LESS FREQUENT DOSING (EVERY TWO MONTHS).
![Page 32: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/32.jpg)
PEGAPTANIB (MACUGEN)
• FIRST VEGF INHIBITOR TO BE APPROVED BY THE FDA (DECEMBER 2004)
• STUDIED IN TWO RANDOMIZED TRIALS WITH A TOTAL OF 1186 PATIENTS AGED ≥50 WITH SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AMD.
• IS ADMINISTERED IN A 0.3 MG DOSE ONCE EVERY 6 WEEKS BY INTRAVITREAL INJECTION.
• OTHER INTRAVITREAL ANTI-VEGF MEDICATIONS PROVIDE GREATER BENEFIT WITH LESS TOXICITY AND PEGAPTANIB IS ONLY RARELY USED FOR AMD
1GRAGOUDAS ES, ADAMIS AP, CUNNINGHAM ET JR, ET AL. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. N ENGL J MED 2004; 351:2805.2VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION (V.I.S.I.O.N.) CLINICAL TRIAL GROUP, CHAKRAVARTHY U, ADAMIS AP, ET AL. YEAR 2 EFFICACY RESULTS OF 2 RANDOMIZED CONTROLLED CLINICAL TRIALS OF PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. OPHTHALMOLOGY 2006; 113:1508.E1.
![Page 33: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/33.jpg)
SCHEDULE
• THE OPTIMAL FREQUENCY FOR INJECTIONS OF VEGF INHIBITORS IS NOT KNOWN, ALTHOUGH BOTH THE MARINA AND ANCHOR TRIALS EVALUATED MONTHLY INTRAVITREAL INJECTIONS. CURRENT USUAL SCHEDULES OF RANIBIZUMAB AND BEVACIZUMAB ARE MONTHLY. MONTHLY INJECTIONS POTENTIALLY INCREASE EXPENSE AND MAY BE POORLY ACCEPTED BY PATIENTS. THE SCHEDULE FOR AFLIBERCEPT IS TO ADMINISTER THREE DOSES (2 MG) AT FOUR WEEK INTERVALS, FOLLOWED BY 2 MG EVERY EIGHT WEEKS.
Discussion
![Page 34: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/34.jpg)
ANTI-VEGF (GENOTYPING TO GUIDE THERAPY)
![Page 35: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/35.jpg)
![Page 36: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/36.jpg)
![Page 37: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/37.jpg)
THERMAL LASER PHOTOCOAGULATION
![Page 38: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/38.jpg)
THERMAL LASER PHOTOCOAGULATION
![Page 39: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/39.jpg)
PHOTODYNAMIC THERAPY
• PHOTODYNAMIC THERAPY INVOLVES INTRAVENOUS INJECTION OF THE PHOTOSENSITIZING DYE VERTEPORFIN JUST PRIOR TO TREATMENT WITH A PHOTO-ACTIVATING LASER APPLIED THROUGH THE EYE WITH A SPECIFIC CONTACT LENS
![Page 40: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/40.jpg)
PHOTODYNAMIC THERAPY
![Page 41: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/41.jpg)
PHOTODYNAMIC THERAPY
![Page 42: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/42.jpg)
PHOTODYNAMIC THERAPY
• THE ROLE FOR PHOTODYNAMIC THERAPY HAS DECREASED WITH THE INCREASING USE OF ANTI-VEGF THERAPY. WE SUGGEST PHOTODYNAMIC THERAPY (WITH OR WITHOUT INTRAVITREAL BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB) FOR PATIENTS WHO FAIL TO RESPOND TO INITIAL ANTI-VEGF THERAPIES.
![Page 43: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/43.jpg)
PHOTODYNAMIC THERAPY AND ANTI-VEGF INJECTION
![Page 44: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/44.jpg)
PHOTODYNAMIC THERAPY AND ANTI-VEGF INJECTION
• THERE WAS NO DIFFERENCE IN CORRECTED VISUAL ACUITY OR LESION AREA BETWEEN GROUPS.1
1SÖDERBERG AC, ALGVERE PV, HENGSTLER JC, ET AL. COMBINATION THERAPY WITH LOW-DOSE TRANSPUPILLARY THERMOTHERAPY AND INTRAVITREAL RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A 24-MONTH PROSPECTIVE RANDOMISED CLINICAL STUDY. BR J OPHTHALMOL 2012; 96:714.
![Page 45: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/45.jpg)
PHOTODYNAMIC THERAPY AND ANTI-VEGF INJECTION
![Page 46: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/46.jpg)
ANTIOXIDANT VITAMINS AND ZINC
• AREDS: REPORT 8: FOUND A STATISTICALLY SIGNIFICANT BENEFIT OF ANTIOXIDANTS PLUS ZINC SUPPLEMENTATION ON PROGRESSION OF EARLY AMD IN ONE EYE IN PATIENTS WITH WET AMD OR VISION LOSS DUE TO AMD IN THE OTHER EYE.
• SUBSEQUENTLY, THE AREDS2 TRIAL FOUND THAT SUBSTITUTION OF LUTEIN AND ZEAXANTHIN FOR BETA-CAROTENE, AND USING A LOWER ZINC DOSE, DID NOT IMPACT THE TREATMENT BENEFIT
![Page 47: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/47.jpg)
ANTIOXIDANT VITAMINS AND ZINC
• AREDS2:• ORIGINAL DOSE ZINC (80 MG AS ZINC OXIDE)• COPPER OXIDE (2 MG)• VITAMIN E (400 IU)• VITAMIN C (500 MG)• LUTEIN (10 MG) • ZEAXANTHIN (2 MG)• BETA-CAROTENE (15 MG)
1THE AGE-RELATED EYE DISEASE STUDY 2 (AREDS2) RESEARCH GROUP, LUTEIN + ZEAXANTHIN AND OMEGA-3 FATTY ACIDS FOR AGE-RELATED MACULAR DEGENERATION THE AGE-RELATED EYE DISEASE STUDY 2 (AREDS2) RANDOMIZED CLINICAL TRIAL. JAMA. 2013;309(19):2005-2015. DOI:10.1001/JAMA.2013.4997.
![Page 48: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/48.jpg)
ANTIOXIDANT VITAMINS AND ZINC (GENOTYPING TO GUIDE THERAPY)
![Page 49: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/49.jpg)
SURGERY (MACULAR TRANSLOCATION)
• MACULAR TRANSLOCATION SURGERY IS EXPERIMENTAL AND INVOLVES MOVING THE MACULA TO A LESS DISEASED AREA OF THE RETINA IN PATIENTS WITH SUBFOVEAL CHOROIDAL NEOVASCULARIZATION.
• THE ADVENT OF EFFECTIVE PHARMACOLOGIC THERAPY HAS LIMITED THE USE OF THIS SURGICAL MODALITY TO PATIENTS WITH LARGE SUBMACULAR HEMORRHAGES, OR PATIENTS UNRESPONSIVE TO VEGF INHIBITORS.
![Page 50: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/50.jpg)
SURGERY (MACULAR TRANSLOCATION)
![Page 51: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/51.jpg)
SURGERY (MACULAR TRANSLOCATION)
• COMPARISON 1 MACULAR TRANSLOCATION VERSUS PHOTODYNAMIC THERAPY, OUTCOME 3 MEAN CHANGE OF VISUAL ACUITY AT 12 MONTHS
![Page 52: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/52.jpg)
SURGERY (MACULAR TRANSLOCATION)
![Page 53: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/53.jpg)
SURGERY (SUBMACULAR SURGERY)
• SUBMACULAR SURGERY INVOLVES THE REMOVAL OF ABNORMAL SUBRETINAL NEOVASCULARIZATION AND LARGE SUBMACULAR HEMORRHAGES, IF PRESENT. CLINICAL TRIALS HAVE BEEN LARGELY DISAPPOINTING, SHOWING LACK OF BENEFIT AND HIGH RATES OF RETINAL DETACHMENT
![Page 54: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/54.jpg)
SURGERY (SUBMACULAR SURGERY)
![Page 55: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/55.jpg)
SURGERY (SUBMACULAR SURGERY)
![Page 56: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/56.jpg)
SURGERY (SUBMACULAR SURGERY)
![Page 57: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/57.jpg)
RADIATION THERAPY
![Page 58: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/58.jpg)
VISUAL AIDS
![Page 59: Update on Age Related Maculopathy](https://reader036.vdocuments.site/reader036/viewer/2022062523/58ece1c01a28abba298b4613/html5/thumbnails/59.jpg)
THANK YOU